tradingkey.logo

Aspire Biopharma Holdings Inc

ASBP
0.098USD
-0.003-2.69%
收盤 12/19, 16:00美東報價延遲15分鐘
4.83M總市值
虧損本益比TTM

Aspire Biopharma Holdings Inc

0.098
-0.003-2.69%

關於 Aspire Biopharma Holdings Inc 公司

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.

Aspire Biopharma Holdings Inc簡介

公司代碼ASBP
公司名稱Aspire Biopharma Holdings Inc
上市日期Feb 18, 2022
CEO- -
員工數量- -
證券類型Ordinary Share
年結日Feb 18
公司地址194 Candelaro Drive, #233
城市HUMACAO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Puerto Rico
郵編00791
電話
網址
公司代碼ASBP
上市日期Feb 18, 2022
CEO- -

Aspire Biopharma Holdings Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Kraig Higginson
Mr. Kraig Higginson
Executive Chairman of the Board
Executive Chairman of the Board
10.53M
--
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
400.00K
--
DR. Edward Kimball
DR. Edward Kimball
Director
Director
125.37K
+0.57%
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Donald G. Fell
Mr. Donald G. Fell
Independent Director
Independent Director
--
--
Mr. Surendra Ajarapu
Mr. Surendra Ajarapu
Director
Director
--
--
Ms. Barbara J. Sher
Ms. Barbara J. Sher
Director
Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Kraig Higginson
Mr. Kraig Higginson
Executive Chairman of the Board
Executive Chairman of the Board
10.53M
--
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
400.00K
--
DR. Edward Kimball
DR. Edward Kimball
Director
Director
125.37K
+0.57%
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Donald G. Fell
Mr. Donald G. Fell
Independent Director
Independent Director
--
--
Mr. Surendra Ajarapu
Mr. Surendra Ajarapu
Director
Director
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 12月2日 週二
更新時間: 12月2日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Higginson (Kraig)
9.80%
Friedman (Lance)
2.05%
Ajjarapu (Surendra K)
1.04%
Crewe Advisors LLC
0.76%
Scheidemann (Ernest J. Jr.)
0.52%
其他
85.82%
持股股東
持股股東
佔比
Higginson (Kraig)
9.80%
Friedman (Lance)
2.05%
Ajjarapu (Surendra K)
1.04%
Crewe Advisors LLC
0.76%
Scheidemann (Ernest J. Jr.)
0.52%
其他
85.82%
股東類型
持股股東
佔比
Individual Investor
13.96%
Corporation
6.69%
Investment Advisor
2.33%
Investment Advisor/Hedge Fund
0.30%
Hedge Fund
0.22%
Research Firm
0.03%
Venture Capital
0.03%
其他
76.44%

機構持股

更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
63
3.12M
4.40%
--
2025Q3
65
3.12M
11.03%
+825.14K
2025Q2
62
2.05M
9.35%
+603.03K
2025Q1
98
1.44M
45.11%
-19.31M
2024Q4
95
589.74K
302.57%
-13.72K
2024Q3
102
603.46K
307.62%
-79.18K
2024Q2
105
682.64K
311.95%
-1.09M
2024Q1
104
1.77M
266.21%
-22.17M
2023Q4
100
1.85M
266.31%
-691.34K
2023Q3
98
2.54M
279.18%
-380.89K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Higginson (Kraig)
10.53M
21.26%
+4.36M
+70.67%
Sep 25, 2025
Friedman (Lance)
2.21M
4.46%
-1.66M
-42.98%
May 06, 2025
Ajjarapu (Surendra K)
1.12M
2.26%
+1.12M
--
Sep 25, 2025
Crewe Advisors LLC
626.85K
1.27%
+313.43K
+100.00%
Jun 30, 2025
Scheidemann (Ernest J. Jr.)
564.17K
1.14%
+3.21K
+0.57%
Sep 25, 2025
Procyon Advisors, LLC
648.41K
1.31%
+549.91K
+558.29%
Jun 30, 2025
The Vanguard Group, Inc.
80.21K
0.16%
--
--
Aug 31, 2025
Doss (Howard A)
400.00K
0.81%
+400.00K
--
Sep 25, 2025
Optivise Advisory Services, LLC
235.11K
0.47%
+128.66K
+120.87%
Jun 30, 2025
Geode Capital Management, L.L.C.
173.38K
0.35%
-11.75K
-6.35%
Aug 31, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
SPAC and New Issue ETF
0%
SPAC and New Issue ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Aspire Biopharma Holdings Inc的前五大股東是誰?

Aspire Biopharma Holdings Inc的前五大股東如下:
Higginson (Kraig)
持有股份:10.53M
佔總股份比例:21.26%。
Friedman (Lance)
持有股份:2.21M
佔總股份比例:4.46%。
Ajjarapu (Surendra K)
持有股份:1.12M
佔總股份比例:2.26%。
Crewe Advisors LLC
持有股份:626.85K
佔總股份比例:1.27%。
Scheidemann (Ernest J. Jr.)
持有股份:564.17K
佔總股份比例:1.14%。

Aspire Biopharma Holdings Inc的前三大股東類型是什麼?

Aspire Biopharma Holdings Inc 的前三大股東類型分別是:
Higginson (Kraig)
Friedman (Lance)
Ajjarapu (Surendra K)

有多少機構持有Aspire Biopharma Holdings Inc(ASBP)的股份?

截至2025Q4,共有63家機構持有Aspire Biopharma Holdings Inc的股份,合計持有的股份價值約為3.12M,占公司總股份的4.40% 。與2025Q3相比,機構持股有所增加,增幅為-6.62%。

哪個業務部門對Aspire Biopharma Holdings Inc的收入貢獻最大?

在--,--業務部門對Aspire Biopharma Holdings Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI